Trial
NCT02863991
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Jazz Pharmaceuticals
Collaborators
Oncoceutics, Inc.
Condition
Multiple Myeloma
Intervention
ONC201
Why stopped
This study was terminated due to a change in corporate priorities. The decision to terminate the study was not based on any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-03